５種の原発巣からのオリゴ肺転移に対する肺ラジオ波焼灼療法の長期成績の後方視的検討 by Omae, Kenichi
1 
 
Clinical Study 
Long-Term Survival after Radiofrequency Ablation of Lung Oligometastases from 5 
types of Primary Lesions: A Retrospective Evaluation 
 
Kenichi Omae
1
, MD, Takao Hiraki
1
, MD, Hideo Gobara
1
, MD, Toshihiro Iguchi
1
, MD, 
Hiroyasu Fujiwara
1
, MD, Yusuke Matsui
1
, MD, Shinichi Toyooka
2
, MD, Takeshi 
Nagasaka
3
, MD, Susumu Kanazawa
1
, MD 
 
Department of Radiology
1
, General Thoracic Surgery
2 
and Gastroenterological Surgery
3
 
Okayama University Medical School,  
2-5-1 Shikatacho, Kita-ku, Okayama 700-8558, Japan 
  
2 
 
Abstract 
Purpose: To conduct a retrospective evaluation of long-term survival after radiofrequency 
(RF) ablation for lung oligometastases from 5 types of primary lesions. 
Materials and Methods: The study population consisted of 123 patients with lung 
oligometastases from colorectal cancer, non-small cell lung cancer, hepatocellular 
carcinoma, esophageal cancer, and renal cell carcinoma, who were treated with RF ablation. 
Lung oligometastases were defined as 1–5 metastases confined to the lung, while the 
primary cancer and other metastases were eradicated. Overall survival (OS) and 
recurrence-free survival (RFS) were estimated for the overall study population, as well as 
for the patients with each type of primary lesion. The OS and RFS rates were compared to 
those of the patients with any of the other four primary lesion types. Finally, various 
variables were analyzed to determine what factors influenced OS and RFS. 
Results: The median follow-up was 45.7 months, and the 5-year OS and RFS rates for all 
123 patients were 62% and 25%, respectively. The OS rate for patients with metastases 
from colorectal cancer was significantly (P = 0.042) longer and that from esophageal 
cancer was significantly (P = 0.022) shorter. Longer disease-free interval was significantly 
(P = 0.015) associated with better OS. There was no variable significantly associated with 
OS and RFS on multivariate analyses. 
Conclusions: This single-center study suggests that the long-term survival data after RF 
ablation of lung oligometastases seems promising. 
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INTRODUCTION 
 The lung is the second most frequent site of metastasis from extra-thoracic cancers 
[1]. For example, approximately 5% of patients who undergo curative resection for 
colorectal cancer develop lung metastasis; the incidence of lung metastasis is following that 
of liver metastasis [2]. Curative local therapy can be applied to oligometastases with the 
aim of long-term survival or even cure. Oligometastases were defined by Hellman and 
Weichselbaum as metastases that are limited in number and location [3, 4].  
 Surgical resection is considered the standard curative local therapy for lung 
metastases. However, many patients are not surgical candidates because of limited organ 
function, comorbidities, refusal to undergo surgery, etc. 
 Radiofrequency (RF) ablation is another local therapy for lung metastasis. RF 
ablation is less invasive, making it an attractive therapy option for nonsurgical candidates. 
Although some studies [5–8] have shown long-term survival of the patients who underwent 
RF ablation of lung metastases from various types of primary cancer, population of those 
studies were not limited to oligometastatic patients. Therefore, long-term survival data 
following RF ablation of lung oligometastases are still lacking. Thus, the purpose of this 
study was to undertake a retrospective evaluation of long-term survival after RF ablation of 
lung oligometastases from 5 types of primary lesions. 
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MATERIALS AND METHODS 
The institutional review board approved this retrospective study (approval number, 
2286) and informed consent was obtained from all patients prior to performing the 
procedure.  
Study Population 
Between June 2001 and December 2013, 556 patients with lung metastases from 
various primary lesions underwent RF ablation at our institution. This study focused on 
lung oligometastases from five types of primary cancer: colorectal cancer (CRC), non-small 
cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal cancer (EC), and 
renal cell carcinoma (RCC). In this study, lung oligometastases were defined as 1–5 
metastases confined to the lung while the primary lesion and other metastases, if they 
existed, were eradicated by any treatment at the time of the initial RF ablation. Patients 
with lung oligometastases from other primary lesions were excluded because they were 
limited in number.  
The inclusion criteria for this study were as follows: (i) lung oligometastases from 
any of the above-mentioned primary lesions; (ii) all lung oligometastases were treated with 
RF ablation; and (iii) follow-up period for surviving patients was longer than 6 months. 
Thus, the patient (n = 1) who survived but was followed for less than 6 months was 
excluded, while the patient (n = 2) who died within 6 months after RF ablation were 
included. The patients who underwent other local therapies (e.g., surgery and stereotactic 
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body radiotherapy) in addition to RF ablation to eradicate lung oligometastases were 
excluded, but patients who underwent concurrent or adjuvant chemotherapy were included 
in this study. 
One hundred twenty-three patients (84 men and 39 women; mean age, 65.6 years; 
range, 34–94 years) with a total of 222 lung oligometastases (mean long-axis tumor 
diameter, 12.5 mm; range, 2–50 mm) met the inclusion criteria. The characteristics of study 
population are summarized in Table 1. This study cohort included 70 patients (CRC, n = 
43; HCC, n = 8; EC, n = 14; RCC, n = 5) who had been previously described elsewhere [9–
12], and their follow-up data were updated for this study. This study was newly conducted 
because it enabled comparison of survival after RF ablation of lung oligometastases among 
the 5 primary lesions. Further, this study was different from the previous studies in that the 
cohort was confined to the patients with lung oligometastases. 
Lung oligometastases were primarily from CRC in 52 patients, NSCLC in 33 
patients, HCC in 16 patients, EC in 14 patients, and RCC in 8 patients. One hundred ninety 
lung metastases were clinically diagnosed based on the results of serial chest computed 
tomography (CT) scans, while 32 metastases were pathologically confirmed by biopsy. 
There was a single lung metastasis and multiple lung metastases in 62 and 61 patients, 
respectively. Ninety-two and 31 patients underwent single and multiple RF ablation 
sessions, respectively. Fifty-six patients had a previous history of pulmonary metastasis, 
extrapulmonary metastasis, or both, all of which were eradicated by any therapy at the time 
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of RF ablation.  
RF Ablation Techniques 
 RF ablation techniques used at our institution were similar to those that have 
previously been described in the literature [13]. RF ablation was always performed in an 
inpatient setting. Intraprocedural pain was treated using a combination of local or epidural 
anesthesia and conscious sedation using fentanyl. The procedure was percutaneously 
carried out under CT-fluoroscopy (Asteion or Aquilion; Toshiba medical, Tochigi, Japan).  
 The electrode used for RF ablation was a multitined expandable electrode 
(LeVeen; Boston Scientific, Natick, MA) or a single internally cooled electrode (Cool-tip; 
Covidien, Mansfield, MA). A multitined expandable electrode was preferred. However, a 
single internally cooled electrode was used in cases where there was a concern that 
expendable tines might result in injury to critical structures, such as large vessels. RF 
ablation was performed with the aim of ablating the tumors with at least 5 mm of marginal 
parenchyma. Each session targeted only one lung; thus, bilateral metastases were treated 
with multiple sessions. 
Follow-up 
 Follow-up sessions were conducted at 1 (range, 4–6 weeks), 3 (2–4), 6 (5–7), 9 (8–
10), and 12 (11–13) months and at 6 (5–7)-month intervals thereafter. At every follow-up 
session, chest and abdominal CT was performed before and, whenever possible, after 
intravenous administration of a contrast agent with 5-mm collimation. The diagnostic 
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criteria for local tumor progression at our institution were similar to those that have 
previously been described in the literature [13]. In short, local tumor progression was 
indicated by the appearance of an irregular, scattered, nodular, or eccentric focus in the 
ablation zone or by circumferential enlargement of the ablation zone. 
Study Endpoint  
  The endpoint of this study was patient survival after RF ablation of lung 
oligometastases. Survival time was calculated from the time of the initial RF ablation. The 
terminal event was death from any cause for the estimation of overall survival (OS) and 
death from any cause or any cancer recurrence for the estimation of recurrence-free 
survival (RFS). First, OS and RFS were estimated for all 123 patients as well as for the 
patients with each type of primary lesion. The OS and RFS rates for the patients with each 
type of primary lesion were compared to those of the patients with any of the other four 
primary lesion types. 
 Second, to determine prognostic factors, various variables were collected, and the 
cohort was divided into two or three groups per variable. Subsequently, OS and RFS were 
compared between the groups. The variables analyzed included age (≤65 y or >65 y), sex 
(male or female), number of metastases (1, 2 or 3–5), size of largest metastasis (≤10 mm, 
11–20 mm or >20 mm), previous history of any metastasis (yes or no), concurrent or 
adjuvant systemic chemotherapy (yes or no), and disease-free interval (≤2 y or >2 y). 
Disease-free interval was the time from therapy for the primary lesion and manifestation of 
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the first metastasis. In this study, survival was calculated from the time of the initial RF 
ablation, not from the time of therapy for the first metastasis. Thus, the follow-up period 
began later for patients with a previous history of metastases. Considering this time lag, the 
comparison of survival in terms of disease-free interval was confined to the patients for 
whom lung RF ablation was the first therapy for the metastases. Subsequently, multivariate 
analyses were performed to determine independent prognostic factors for OS and RFS. The 
variable of disease-free interval was excluded from the analyses, because data were 
collected from limited patients as described above. All other variables were included in the 
analyses. 
Statistical Analysis 
 Survival was estimated with the Kaplan-Meier method and univariate analyses 
were performed by the log-rank test to compare the survival rates. Multivariate analyses to 
determine the independent prognostic factors were performed using the Cox 
proportional-hazards model. For all analyses, a P value of <0.05 was considered 
statistically significant. Statistical analyses were performed using the Statistical Package for 
the Social Sciences software (version 22.0; IBM Corp, Armonk, New York). 
 
RESULTS 
Concurrent or adjuvant chemotherapy was utilized in 41 patients. There was no 
mortality related to RF ablation. The median (mean) follow-up period for all 123 patients 
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was 45.7 (52.5) months. After RF ablation, 30% (37/123) of the patients were free from 
cancer recurrence until the last follow-up, and the remaining 70% (86/123) of the patients 
had developed recurrence. Seventy-one of the 86 patients with recurrence underwent the 
treatment for the recurrence. Data on the site of recurrence, the therapy for recurrence, and 
survival after RF ablation are shown in Table 2.  
The 5-year OS and RFS rates for all 123 patients were 62% and 25%, respectively 
(Figure 1 and Table 3). The 5-year OS and RFS rates were 70% and 30%, 61% and 16%, 
66% and 32%, 33% and 19%, and 47% and 25% for the patients with lung oligometastases 
from CRC, NSCLC, HCC, EC, and RCC, respectively (Figure 2, 3 and Table 3). The OS 
rate for patients with lung oligometastases from CRC were significantly (P = 0.042) longer 
and the OS rate for patients with lung oligometastases from EC were significantly (P = 
0.022) shorter than the OS rates for patients with the other four primary lesion types (Table 
3). In contrast, RFS rate was not significantly different between the five primary lesion 
types (Table 3).  
The results of univariate and multivariate analyses performed to determine the 
factors that influenced OS and RFS in patients with lung oligometastases treated with RF 
ablation are shown in Table 4 and Table 5. In the univariate analyses, a disease-free 
interval >2 years and female patients were associated with longer OS (P = 0.015 and 0.043, 
respectively) but were not significantly associated with RFS. A smaller number of lung 
metastases was significantly associated with longer RFS (P = 0.033). The other variables 
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analyzed, including size of metastases and previous history of metastases, and concurrent or 
adjuvant chemotherapy were not significantly associated with OS or RFS. In the 
multivariate analyses, although female patients tended to associate with better OS and 
smaller number of lung metastases tended to associate with better RFS, there was no 
independent prognostic factors for OS and RFS. 
   
DISCUSSION 
 Surgical resection is considered the most radical therapy for lung metastasis. 
Recent studies have shown that the 5-year survival rates after resection of lung metastases 
from various primary lesions range from 36% to 46% [14, 15]. The 5-year survival rate 
after resection of metastases from CRC, HCC, EC, and RCC are 54%–57% [16, 17], 37%–
41% [18, 19], 34% [20] and 45% [21], respectively. In this study, the follow-up period 
started later for the 56 (46%) patients with a previous history of pulmonary metastases than 
is typical for studies of surgical resection of metastases. Nevertheless, the survival data of 
our study seem quite promising. 
de Baère et al. [5] recently reported the survival outcomes of 566 patients after RF 
ablation of lung metastases in a multicenter prospective study. The primary tumor type was 
variable, but it was CRC in 52% of the patients. The median follow-up period was 36 
months, and the 5-year OS was 51.5%. Type of primary tumor, disease-free interval, and 
number of lung metastases were associated with OS. Chua et al. [6] reported prospective 
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survival outcomes of 140 patients with lung metastases treated by RF ablation. The primary 
tumor type was CRC in 77% of the patients. The median follow-up period was 29 months, 
and the 3-year and 5-year OS rates were 60% and 45%, respectively. The 3-year and 5-year 
survival rates after RF ablation of colorectal metastases were 57%–72% [7, 8, 10] and 
50%–52% [7, 10], respectively. Our retrospective study revealed a 5-year OS rate of 62% 
and a median survival time of 90 months for patients with lung oligometastases from 5 
types of primary lesion types over a median follow-up period of 46 months. Of note, 30% 
of the patients survived without cancer recurrence, which indicates that RF ablation is a 
potentially curative treatment for patients with lung oligometastases. Stereotactic body 
radiation therapy (SBRT), another local therapy for lung metastases, may be competitive 
with RF ablation in terms of survival. Recent studies have shown that the 2-year and 5-year 
OS rates of patients with lung metastases treated with SBRT are 60%–84% and 49%–56%, 
respectively [14, 22]. Survival outcomes after therapy for lung metastases, regardless of the 
type of therapy (metastasectomy, RF ablation, or SBRT), are similar.  
 In this study, the OS rate for patients with metastases from CRC seems longer and 
the OS rate for patients with metastases from EC seems shorter than the OS rates for 
patients with the other four primary lesion types. In contrast, RFS does not seem different 
between the five primary lesion types. This discrepancy between the differences in OS and 
RFS when comparing the patients with different primary lesion types may mainly be due to 
differences in the aggressiveness of recurrence among the different primary lesion types. 
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However, as the number of patients with each primary lesion type was too small, our results 
cannot be conclusive. Therefore, a larger study is necessary to draw final conclusions on 
the relationship between survival and primary lesion type. 
 In our study, longer disease-free interval was significantly associated with better 
OS in the univariate analysis. However, none of the variables were significantly associated 
with OS and RFS in the multivariate analyses. Based upon the results, we suggest that RF 
ablation be considered regardless of the size or number (up to 5) of metastases because 
neither of these two factors significantly affected OS. Similarly, we suggest that patients 
with a history of metastasis should also be treated with RF ablation if the previous 
metastasis completely resolved because survival was not significantly different between 
patients with a previous history of metastasis and those without it. The patients with a 
shorter disease-free interval had a significantly shorter OS. This may be due to the more 
aggressive nature of tumors that progress in a shorter interval. Similar results have been 
reported in surgical literatures [15, 17, 22, 23].  
 Our study has various limitations. This was a retrospective, single-center study 
with a limited population size. The therapies implemented for recurrence after lung RF 
ablation depended on cancer state and patient condition. In other words, the treatment 
strategy for recurrence was individualized and was not uniform among patients. The 
survival outcomes shown in this study resulted not only from lung RF ablation but also 
from multidisciplinary treatments for previous metastases and recurrence after RF ablation. 
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Although our survival outcomes seem encouraging, this study did not show any survival 
advantage of RF ablation over other therapies, such as metastasectomy and SBRT. One 
may indicate the issue of competing risk when estimating RFS by the Kaplan-Meier 
method. However, we considered that competing risk was too small to affect the outcomes 
considerably, because this study included only two patients who were dead without 
recurrence. Finally, there are residual survival factors to be evaluated. For example, 
mutations such as KRAS for CRC and epidermal growth factor receptor for NSCLC have 
prognosis implications. However, data on such mutations were missing in many patients 
and thus those were not evaluated. 
 In conclusion, the observed survival outcomes after RF ablation of lung 
oligometastases from the 5 types of primary lesions seem promising. A longer disease-free 
interval was significantly associated with better OS.  
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CRC (52) NSCLC (33) HCC (16) EC (14) RCC (8) All (123) 
Mean 66 68 62 65 63 66 
Range 37–94 48–84 35–82 44–75 34–77 34–94 
Male 30 23 11 14 6 84 
Female 22 10 5 0 2 39 
Median (mean) 50 (55) 54 (59) 26 (45) 35 (42) 43 (49) 46 (53) 
Range 9–128 5–129 2–121 12–94 28–87 2–129 
  
1/2/3/4/5 25/15/9/1/2 20/8/3/1/1 4/7/2/2/1 9/4/1/0/0 4/3/0/0/1 62/37/15/4/5 
Median 2 1 2 1 1.5 1 
Single 38 30 7 11 6 92 
Multiple 14 3 9 3 2 31 
Tumor size (mm) Mean 12.0 12.9 12.2 15.0 11.6 12.5 
Range 3–33 2–30 3–50 6–28 3–37 2–50 
Multitined expandable electrode 84 42 31 12 14 183 
Internally cooled 12 12 6 8 1 39 
Pulmonary only 20 4 7 2 5 38 
Extra pulmonary only 7 3 0 2 1 13 
Both 3 1 1 0 0 5 
None 22 25 8 10 2 67 
Concurrent or adjuvant 
systemic chemotherapy 
21 6 3 8 3 41 
Table 1. Characteristics of All 123 Patients Treated by RF Ablation. 
RF = radiofrequency, CRC = colorectal cancer, NSCLC = non-small cell lung cancer, HCC = hepatocellular carcinoma, EC = esophageal cancer, RCC = 
renal cell carcinoma.  
Primary cancer (No. of patients) 
Variable 
No. of sessions 
No. of tumors 
Follow up period (mo) 
Sex 
Age (y) 
Electrode type 
 (No. of tumors) 
Previous metastases 
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CRC (52) NSCLC (33) HCC (16) EC (14) RCC (8) All (123) 
Site of recurrence after RF ablation 
None 18 9 4 4 2 37 
17 14 6 5 3 45 
13 8 3 3 1 28 
Lymph node     3     3     2     8 
Liver     5     1     6 
Lymph node and liver     1     1 
Pleura     4     4 
Peritoneum     1     1     2 
Bone     1     1     2 
Bone and liver     1     1 
Brain     2     1     3 
Pancreas     1     1 
4 2 3 2 2 13 
Lymph node     4     2     1     1     8 
Bone     2     2 
Liver     1     1     2 
Adrenal     1     1 
Median (Mean) 15 (47) 15 (25) 11 (31) 6.2 (41) 29 (41) 15 (29) 
Range 1.2–127 1.1–110 1.0–116 1.3–94 8.5–87 1.1–127 
23 15 6 5 4 53 
RF ablation     13     12     2     2     2     31 
Surgery     9     1     1     1     2     14 
RT     1     1     1     3 
TACE     2     2 
RF ablation and RT     1     1     2 
RF ablation and surgery     1     1 
6 2 2 0 2 12 
1 1 0 4 0 6 
RT     1     3     4 
RF ablation     1     1 
Surgery     1     1 
None 3 5 4 1 0 13 
NA 1 1 0 0 0 2 
Cause of death 
Alive 37 16 10 5 4 72 
Died of cancer  11 10 4 6 3 34 
Died of other disease 4 7 2 3 1 17 
Table 2. Information on Cancer State and Patient Survival after RF Ablation of Lung Metastases 
Primary cancer (No. of patients) 
Variable 
RF = radiofrequency, CRC = colorectal cancer, NSCLC = non-small cell lung cancer, HCC = hepatocellular carcinoma, EC = esophageal 
cancer, RCC = renal cell carcinoma, NA = data not available, RT = radiation therapy, TACE = transcatheter arterial 
chemoembolization. 
 
 
Lung only 
Extra-lung only 
Local therapy only 
Systemic chemotherapy only 
Both (with systemic chemotherapy) 
Both (with lung) 
Therapy for recurrence after RF ablation 
Recurrence-free interval (mo) 
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Time (mo) Time (mo) 
Median (Mean) 1 y 2y 3y 4y 5y P  value* Median (Mean) 1 y 2y 3y 4y 5y P  value* Median (Mean) 
CRC 52 50 (55) 98 89 84 76 70 0.042** NR (93) 56 43 35 30 30 0.46 15 (47) 
NSCLC 33 54 (59) 97 84 76 68 61 0.71 90 (80) 63 32 28 25 16 0.59 15 (33) 
HCC 16 26 (45) 94 66 66 66 66 0.85 121 (85) 47 40 40 32 32 0.67 11 (32) 
EC 14 35 (42) 93 77 62 44 33 0.022** 42 (50) 50 36 29 29 19 0.47 6 (29) 
RCC 8 43 (49) 100 100 70 70 47 0.58 58 (60) 88 75 38 25 25 0.43 29 (41) 
All 123 46 (53) 95 83 76 68 62 90 (82) 58 41 33 28 25 17 (41) 
RF = radiofrequency, CRC = colorectal cancer, NSCLC = non-small cell lung cancer, HCC = hepatocellular 
carcinoma, EC = esophageal cancer, RCC = renal cell carcinoma, NR = not reached, *Survival rates were 
compared between corresponding cancer and other four types with the log-rank test, **statistically significant. 
 
Table 3. Results of Survival of the Patients with Lung Oligometastasis from Each Type of Primary Lesion 
Treated with RF Ablation 
Primary 
cancer 
No. of 
patients 
Rate (%) Rate (%) 
Overall survival Recurrence-free survival Follow-up 
period (mo) 
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1 y 3y 5y P  value HR (95% CI) P  value 
≤65 55 95 80 70 0.058 1.00 Ref 
>65 68 96 72 54 1.72 (0.92–3.22) 0.088 
Male 84 94 72 57 0.043* 1.00 Ref 
Female 39 97 85 74 0.50 (0.24–1.04) 0.063 
1 62 97 78 60 0.85 1.00 Ref 
2 37 97 77 62 0.67 (0.30–1.50) 0.33 
3–5 24 88 69 69 0.53 (0.21–1.31) 0.17 
≤10 34 100 83 78 0.081 1.00 Ref 
11–20 66 97 75 60 0.50 (0.20–1.25) 0.14 
>20 23 83 70 51 0.87 (0.43–1.75) 0.67 
No 67 94 74 59 0.55 1.00 Ref 
Yes 56 97 78 66 1.00 (0.55–1.83) 0.99 
No 82 95 75 60 0.59 1.00 Ref 
Yes 41 95 78 69 0.86 (0.42–1.79) 0.69 
≤2 34 88 63 45 0.015* 
>2 33 100 87 75 
Disease-free 
interval (y)** 
RF = radiofrequency, HR = hazard ratio, CI = confidence interval, Ref = reference value. *statistically 
significant, **Univariate analysis was performed confined to patients in whom RF ablation of lung 
metastases was the first treatment of metastasis, and this variable was excluded from multivariate 
analysis.  
 
Age (y) 
Sex 
No. of lung 
metastases 
Largest size of lung 
metastases (mm) 
Previous history of 
metastases 
Concurrent or 
adjuvant systemic 
chemotherapy 
Table 4. Results of Univariate and Multivariate Analyses to Determine Prognostic Factors for Overall 
Survival in Patients with Lung Oligometastasis Treated with RF Ablation  
Variable 
No. of 
patients 
Univariate analysis Multivariate analysis 
Overall survival rate 
(%) 
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1 y 3y 5y P  value HR (95% CI) P  value 
≤65 55 56 35 27 0.97 1.00 Ref 
>65 68 60 31 22 1.06 (0.69–1.63) 0.80 
Male 84 57 29 22 0.17 1.00 Ref 
Female 39 62 41 31 0.73 (0.44–1.21) 0.22 
1 62 67 38 30 0.033* 1.00 Ref 
2 37 56 31 22 0.58 (0.33–1.02) 0.059 
3–5 24 38 22 15 0.75 (0.40–1.41) 0.38 
≤10 34 62 36 33 0.87 1.00 Ref 
11–20 66 55 30 19 1.16 (0.55–2.44) 0.71 
>20 23 63 37 31 1.44 (0.76–2.75) 0.26 
No 67 63 33 24 0.69 1.00 Ref 
Yes 56 53 33 27 1.03 (0.68–1.60) 0.85 
No 82 62 46 26 0.34 1.00 Ref 
Yes 41 51 32 22 1.23 (0.78–1.95) 0.37 
≤2 34 59 28 24 0.83 
>2 33 67 37 23 
Disease-free 
interval (y)** 
RF = radiofrequency, HR = hazard ratio, CI = confidence interval, Ref = reference value. *statistically 
significant, **Univariate analysis was performed confined to patients in whom RF ablation of lung 
metastases was the first treatment of metastasis, and this variable was excluded from multivariate 
analysis. 
 
 
Age (y) 
Sex 
No. of lung 
metastases 
Largest size of lung 
metastases (mm) 
Previous history of 
metastases 
Concurrent or 
adjuvant systemic 
chemotherapy 
Table 5. Results of Univariate and Multivariate Analyses to Determine Prognostic Factors for Recurrence-free 
Survival in Patients with Lung Oligometastasis Treated with RF Ablation 
 
 
Variable 
No. of 
patients 
Univariate analysis Multivariate analysis 
Recurrence-free 
survival rate (%)  
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Figure 1. Overall survival rates and recurrence-free survival rates of 123 patients after 
radiofrequency ablation estimated by the Kaplan-Meier method. 
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Figure 2. Overall survival rates of patients with each type of primary cancer.  
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Figure 3. Recurrence -free survival rates of patients with each type of primary cancer. 
 
